Alnylam Pharmaceuticals (ALNY) Other Gross PP&E Adjustments (2017 - 2025)
Alnylam Pharmaceuticals (ALNY) has disclosed Other Gross PP&E Adjustments for 13 consecutive years, with $606.6 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Other Gross PP&E Adjustments rose 7.93% year-over-year to $606.6 million, compared with a TTM value of $606.6 million through Dec 2025, up 7.93%, and an annual FY2025 reading of $606.6 million, up 7.93% over the prior year.
- Other Gross PP&E Adjustments was $606.6 million for Q4 2025 at Alnylam Pharmaceuticals, up from -$191.4 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $606.6 million in Q4 2025 and bottomed at -$238.1 million in Q2 2021.
- Average Other Gross PP&E Adjustments over 5 years is -$31.5 million, with a median of -$197.8 million recorded in 2024.
- Peak annual rise in Other Gross PP&E Adjustments hit 24.19% in 2021, while the deepest fall reached 7.2% in 2021.
- Year by year, Other Gross PP&E Adjustments stood at $392.9 million in 2021, then grew by 17.57% to $462.0 million in 2022, then increased by 14.35% to $528.2 million in 2023, then grew by 6.39% to $562.0 million in 2024, then increased by 7.93% to $606.6 million in 2025.
- Business Quant data shows Other Gross PP&E Adjustments for ALNY at $606.6 million in Q4 2025, -$191.4 million in Q3 2025, and -$192.4 million in Q2 2025.